RPN2 gene confers docetaxel resistance in breast cancer

Nature Medicine
Kimi HonmaTakahiro Ochiya

Abstract

Drug resistance acquired by cancer cells has led to treatment failure. To understand the regulatory network underlying docetaxel resistance in breast cancer cells and to identify molecular targets for therapy, we tested small interfering RNAs (siRNAs) against 36 genes whose expression was elevated in human nonresponders to docetaxel for the ability to promote apoptosis of docetaxel-resistant human breast cancer cells (MCF7-ADR cells). The results indicate that the downregulation of the gene encoding ribophorin [corrected] II (RPN2), which is part of an N-oligosaccharyl transferase complex, most efficiently induces apoptosis of MCF7-ADR cells in the presence of docetaxel. RPN2 silencing induced reduced glycosylation of the P-glycoprotein, as well as decreased membrane localization, thereby sensitizing MCF7-ADR cells to docetaxel. Moreover, in vivo delivery of siRNA specific for RPN2 markedly reduced tumor growth in two types of models for drug resistance. Thus, RPN2 silencing makes cancer cells hypersensitive response to docetaxel, and RPN2 might be a new target for RNA interference-based therapeutics against drug resistance.

References

Oct 1, 1996·Current Opinion in Genetics & Development·M M GottesmanS V Ambudkar
Feb 16, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J BonneterreM Mahjoubi
Aug 11, 2001·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Johan RenesMichael Müller
Dec 14, 2001·Biochemical and Biophysical Research Communications·K HonmaM Terada
Jul 18, 2002·Nature Reviews. Drug Discovery·Jason Y Zhang
Jul 18, 2002·Nature Reviews. Drug Discovery·John C Reed
Sep 10, 2002·Chemotherapy·Patrick GuensbergBurkhard Jansen
Mar 1, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Silvia C FormentiFranco Muggia
Mar 26, 2003·Endocrine-related Cancer·F Leonessa, R Clarke
May 29, 2003·Current Medicinal Chemistry. Anti-cancer Agents·Olivier SordetYves Pommier
Jun 28, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Manfred KaufmannHans-Jörg Senn
Dec 19, 2003·Nucleic Acids Research·Michael Y Galperin
Aug 24, 2004·Molecular Pharmacology·Zhigang ZhangJin-Ming Yang
Jan 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kyoko Iwao-KoizumiKikuya Kato
May 21, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·W J GradisharS M Swain
Jul 14, 2005·British Journal of Cancer·F K EngelsJ Verweij
Aug 11, 2005·Proceedings of the National Academy of Sciences of the United States of America·Fumitaka TakeshitaTakahiro Ochiya
Aug 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E JonesP M Ravdin
Dec 1, 2005·Glycobiology·Daniel J Kelleher, Reid Gilmore
Dec 3, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Seung Jin KimShinzaburo Noguchi
Feb 1, 2007·Expert Opinion on Drug Discovery·Takahiro OchiyaShunji Nagahara

❮ Previous
Next ❯

Citations

May 27, 2011·Journal of Inherited Metabolic Disease·Elisabeth MohorkoMarkus Aebi
Apr 7, 2011·Archives of Pharmacal Research·Hun Soon Jung, Young Kee Shin
Oct 1, 2009·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Sadako Akashi-Tanaka
Apr 15, 2011·Gene Therapy·D Peer, J Lieberman
Oct 28, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Shinichiro InabaYoshifumi Takei
Jun 25, 2009·Proceedings of the National Academy of Sciences of the United States of America·Benjamin L SchulzMarkus Aebi
Aug 24, 2011·Molecular & Cellular Proteomics : MCP·Miyako NakanoNicolle H Packer
Oct 14, 2011·Bioinformatics·A Sofia SilvaJoão Pedro de Magalhães
Nov 19, 2013·Genome Génome / Conseil National De Recherches Canada·Mohammad M Ghahramani SenoStephen W Scherer
Sep 3, 2011·Journal of Clinical Bioinformatics·Eri KawataTaira Maekawa
Jun 26, 2010·Breast Cancer Research : BCR·Joshua A BauerJennifer A Pietenpol
Apr 23, 2013·Journal of Cell Science·Audrey Dumax-VorzetStephen High
Jan 1, 2009·International Journal of General Medicine·Kimi HonmaTakahiro Ochiya
May 16, 2014·Nature Communications·Yi-Zhou JiangZhi-Ming Shao
Sep 3, 2014·Molecular Therapy. Nucleic Acids·Tomohiro FujiwaraTakahiro Ochiya
Aug 5, 2015·Journal of Clinical Medicine·Hun Soon JungYoung Kee Shin
Mar 11, 2015·International Journal of Molecular Sciences·Yu FujitaTakahiro Ochiya
Apr 11, 2015·Cancers·Ryou-U TakahashiTakahiro Ochiya
May 31, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jing ZhangLeaf Huang
Jan 7, 2016·Nanomedicine : Nanotechnology, Biology, and Medicine·Ping WangXintao Shuai
Feb 13, 2016·Proceedings of the National Academy of Sciences of the United States of America·Alan S L WongTimothy K Lu
Apr 30, 2010·Biomaterials·Xiao-Bing XiongAfsaneh Lavasanifar
Jul 31, 2009·International Journal of Cancer. Journal International Du Cancer·Akihito NaganoYoshifumi Takei
Nov 19, 2013·Journal of Cellular Biochemistry·Michael Welti, Andreas J Hülsmeier
Jun 3, 2014·Molecular Cancer·Naoomi TominagaTakahiro Ochiya
Apr 18, 2015·Pathology International·Makiko OnoTakahiro Ochiya
Aug 19, 2015·Nature Biotechnology·Alan S L WongTimothy K Lu
Jun 13, 2015·Nature Communications·Ryou-u TakahashiTakahiro Ochiya
Jul 14, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Dan Peer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Tumorigenesis

Breast tumorigenesis involves the production or formation of tumor(s) in breast tissue. Discover the latest research on breast tumorigenesis here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis